Roberts Lydia E, Williams Chloe E C, Oni Louise, Barratt Jonathan, Selvaskandan Haresh
John Walls Renal Unit, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, United Kingdom.
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Indian J Nephrol. 2024 Jul-Aug;34(4):297-309. doi: 10.25259/ijn_425_23. Epub 2024 Jun 24.
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis reported across the world and is characterized by immunoglobulin A (IgA) dominant mesangial deposits, which are poorly -glycosylated. This deposition leads to a cascade of glomerular and tubulointerstitial inflammation and fibrosis, which can progress to chronic kidney disease. The variability in rate of progression reflects the many genetic and environmental factors that drive IgAN. Here, we summarize the contemporary understanding of the disease mechanisms that drive IgAN and provide an overview of new and emerging therapies, which target these mechanisms.
免疫球蛋白A肾病(IgAN)是全球报道的最常见的原发性肾小球肾炎,其特征是免疫球蛋白A(IgA)为主的系膜沉积,这些沉积物糖基化程度低。这种沉积导致一系列肾小球和肾小管间质炎症及纤维化,可进展为慢性肾脏病。进展速度的变异性反映了驱动IgAN的许多遗传和环境因素。在此,我们总结了对驱动IgAN的疾病机制的当代理解,并概述了针对这些机制的新出现的治疗方法。